Elsevier

The American Journal of Cardiology

Volume 188, 1 February 2023, Pages 95-101
The American Journal of Cardiology

Clinical Significance of Culprit Vessel Occlusion in Patients With Non–ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention

https://doi.org/10.1016/j.amjcard.2022.11.013Get rights and content

In patients with non–ST-elevation myocardial infarction (NSTEMI), total occlusion of the culprit coronary artery (OCA) is not uncommon. We sought to determine the frequency and clinical impact of OCA at presentation in a large population of patients presenting with NSTEMI and who underwent systematic early invasive management. We performed a post hoc analysis of the TAO (Treatment of Acute Coronary Syndrome with Otamixaban) randomized trial, which included patients with NSTEMI with systematic coronary angiography within 72 hours. We compared the baseline characteristics and outcomes of patients according to whether the culprit vessel was occluded (thrombolysis in myocardial infarction flow grade [TFG] 0 to 1) or patent (TFG 2 to 3) at presentation. A total of 7,473 patients with NSTEMI with only 1 culprit lesion identified were enrolled, of whom 1,702 patients had OCA (22.8%). In the OCA group, coronary angiography was performed earlier (18 ± 15 vs 20 ± 16 hours, p <0.01), the culprit lesion was less likely to be the left anterior descending artery (26.5% vs 41.4%, p <0.001) but with more frequent angiographic thrombus (49.9% vs 22.7%, p <0.01). Culprit artery percutaneous coronary intervention during the index procedure was also more frequent (88.5% vs 78.1%, p <0.001) but with a lower rate of TFG grade 3 after the procedure and higher subsequent peak troponin I levels (8.3 ± 13.6 µg/L vs 5.6 ± 11.9 µg/L, p <0.001). At day 7, patients with OCA had higher mortality, and this persisted after adjustment on gender, Grace risk score, cardiovascular risk factors, and culprit vessel location (0.9% vs 0.4%, p = 0.02; adjusted odds ratio [OR] = 2.55, 95% confidence interval [CI] 1.23 to 5.29, p = 0.01). The absolute difference of mortality was maintained through 30 days: 1.2% versus 0.8%, p = 0.13; OR: 1.72, 95% CI 0.97 to 3.05, but mortality rates were similar by 180 days: 1.5% versus 1.6%, p = 0.8, adjusted OR = 1.11, 95% CI 0.69 to 1.80, p = 0.66. In conclusion, a significant proportion of patients with NSTEMI have a totally occluded culprit vessel at presentation. These patients are at higher risk of early mortality but not at 6 months.

Section snippets

Methods

The design and main results of the TAO trial have been published.14, 15, 16 Briefly, the TAO trial was a large, international, randomized trial, enrolling patients with moderate- to high-risk NSTEMI scheduled to undergo coronary angiography (and revascularization if indicated) within 72 hours of symptom onset. To participate in the trial, patients had to have ischemic symptoms at rest for ≥10 minutes within 24 hours of randomization and at least 1 of the 2 following criteria: (1) new ST-segment

Results

The study population comprised 7,473 patients with NSTEMI with a single culprit lesion, who underwent coronary angiography. Among these, 1,702 patients (22.8%) had a TFG 0/1 culprit vessel at presentation (OCA group). Briefly, patients in the OCA group were younger (p <0.001); more likely to be men (p <0.001); with lower rates of diabetes (p <0.001), hypertension (p <0.001), and dyslipidemia (p <0.001). A coronary artery disease (p <0.001) and previous coronary revascularization (PCI or

Discussion

The main findings of this study were that: (1) approximately 1/5 of patients presenting with NSTEMI had an occluded culprit artery, and (2) 7-day all-cause and CV mortality were higher than in patients with a patent culprit artery and this difference persisted through 30 days, but thereafter, having an occluded culprit artery did not confer an increased hazard of 6-month- mortality.

To the best of our knowledge, this is the largest analysis of patients with NSTEMI according to culprit vessel

Disclosures

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article:

Dr. Ducrocq speaker and/or consulting fees: Abbott, Amgen, Astra Zeneca, Bayer, Bristol-Myers Squibb, Novo Nordisk, Sanofi proctoring: Boston Scientific; Novo Nordisk; research grants: Abbott, AstraZeneca, Amgen, Boston Scientific, Janssen; Dr. Sabate: consultant fees from Abbott Vascular and IVascular, stent manufacturers, outside the scope of this

References (29)

  • Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

    Lancet

    (2016)
  • JP Collet et al.

    2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

    Eur Heart J

    (2021)
  • B Ibanez et al.

    2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)

    Eur Heart J

    (2018)
  • MC Kim et al.

    Impact of total occlusion of an infarct-related artery on long-term mortality in acute non-ST-elevation myocardial infarction patients who underwent early percutaneous coronary intervention

    Int Heart J

    (2012)
  • Funding: none.

    Executive Steering Committee members: Ph.G. Steg (Chair), C. Bode, S. Mehta, C.V. Pollack, M.S. Sabatine, S.D. Wiviott.

    Steering Committee Members:

    J.L. Navarro Estrada (Argentina), D. Brieger (Australia), K. Huber (Austria), N. Mitkovskaya (Belarus), P. Sinnaeve (Belgium), J.C. Nicolau (Brazil), I. Petrov (Bulgaria), M. Grigorov (Bulgaria), S. Mehta (Canada), R. Corbalan (Chile), C. Jaramillo (Colombia), M. Bergovec (Croatia), P. Widimsky (Czech Republic), A. Mowafy (Egypt), P. Laanmets (Estonia), F. Schiele (France), C. Bode (Germany), P.S. Konstantinidis (Greece), K.H. Sim (Hong Kong), R. Kiss (Hungary), P. Kerkar (India), K.H. Sim (Indonesia), H. Hod (Israel), C. Cavallini (Italy), M. Ho Jeong (Korea South), K. Jae-Hyung (Korea South), A. Erglis (Latvia), S. Kabbani (Lebanon), B.Petrauskiene (Lithuania), K.H. Sim (Malaysia), G.A. Ramos (Mexico), W. Jukema (Netherlands), H.D. White (New Zealand), J.E. Nordrehaug (Norway), R.N. Ortega (Panama), J.A. Aguero Rodriguez (Peru), W. Ruzyllo (Poland), L. Providencia (Portugal), M. Dorobantu (Romania), R. Mikhail (Russia), S. Dodic (Serbia), K.H. Sim (Singapore), A. Okreglicki (South Africa), M. Sabaté Tenas (Spain), N. Ruiz (Spain), T. Moccetti (Switzerland), K.H. Sim (Taiwan), K.H. Sim (Thailand), H. Haouala (Tunisia), M. Sezer (Turkey), S. Guneri (Turkey), A. Parkhomenko (Ukraine), A.H. Gershlick (United Kingdom), M. Cohen (United States), J.Hoekstra (United States), S. Rao (United States), W. French (United States, D. Faxon (United States), L. Nguyen (Vietnam).

    View full text